Adefovir Dipivoxil
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317160

CAS#: 142340-99-6

Description: Adefovir dipivoxil (trade names Preveon and Hepsera) is an antiviral acyclic nucleoside phosphonate (ANP) analog. It is a dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV). It is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) that works by blocking reverse transcriptase for the treatment of hepatitis B. Adefovir dipivoxil is not effective against HIV-1.


Price and Availability

Size
Price

100mg
USD 250
1g
USD 950
Size
Price

200mg
USD 450
2g
USD 1650
Size
Price

500mg
USD 650
5g
USD 2950

Adefovir Dipivoxil, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 317160
Name: Adefovir Dipivoxil
CAS#: 142340-99-6
Chemical Formula: C20H32N5O8P
Exact Mass: 501.19885
Molecular Weight: 501.48
Elemental Analysis: C, 47.90; H, 6.43; N, 13.97; O, 25.52; P, 6.18


Related CAS #: 142340-99-6 (Adefovir Dipivoxil)   142340-99-6 (Adefovir free acid)    

Synonym: 9-(2-((-bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine, GS 840, GS-0840, Hepsera; Preveon.

IUPAC/Chemical Name: [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate

InChi Key: WOZSCQDILHKSGG-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)

SMILES Code: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Lin RZ, Sun PJ, Tao Q, Yao J, Chen JM, Lu TB. Mechanism study on stability enhancement of adefovir dipivoxil by cocrystallization: Degradation kinetics and structure-stability correlation. Eur J Pharm Sci. 2015 Oct 10. pii: S0928-0987(15)30035-X. doi: 10.1016/j.ejps.2015.10.006. [Epub ahead of print] PubMed PMID: 26462447.

2: Ning HB, Li K, Li W, Ding GQ, Xiao EH, Mao ZS, Kang Y, Shang J. [Adefovir dipivoxil effects on and related factors of blood phosphorus metabolism in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2015 Aug 20;23(8):590-3. doi: 10.3760/cma.j.issn.1007-3418.2015.08.007. Chinese. PubMed PMID: 26447622.

3: Gu J, Sun R, Shen S, Yu Z. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pak J Pharm Sci. 2015 Jul;28(4 Suppl):1493-7. PubMed PMID: 26431662.

4: Zhu H, Yuan X, Tang L, Hu P, Cai D, Ren F, Huang W. [Clinical analysis of Fanconi syndrome induced by adefovir dipivoxil]. Zhonghua Gan Zang Bing Za Zhi. 2015 Apr;23(4):302-3. Chinese. PubMed PMID: 26427083.

5: Chen Z, Ma X, Zhao Y, Wang J, Zhang Y, Zhu Y, Wang L, Chen C, Wei S, Yang Z, Gong M, Shen H, Bai Z, Guo Y, Niu M, Xiao X. Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2015;2015:529636. doi: 10.1155/2015/529636. Epub 2015 Aug 11. Review. PubMed PMID: 26347789; PubMed Central PMCID: PMC4548141.

6: De Clercq E. Current treatment of hepatitis B virus infections. Rev Med Virol. 2015 Jul 23. doi: 10.1002/rmv.1849. [Epub ahead of print] PubMed PMID: 26205627.

7: Česnek M, Jansa P, Šmídková M, Mertlíková-Kaiserová H, Dračínský M, Brust TF, Pávek P, Trejtnar F, Watts VJ, Janeba Z. Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis. ChemMedChem. 2015 Aug;10(8):1351-64. doi: 10.1002/cmdc.201500183. Epub 2015 Jul 1. PubMed PMID: 26136378.

8: Yao N, Wang C, Yu Z, Zhao K, Kang W, Liu Q, Dang B, Sun Y. [Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos(t)ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load]. Zhonghua Gan Zang Bing Za Zhi. 2015 Apr;23(4):250-3. doi: 10.3760/cma.j.issn.1007-3418.2015.04.004. Chinese. PubMed PMID: 26133814.

9: Wang Y, Shan X, Liang Z, Shan Y, Huang W, Zhang D, Zen A, Zhou X, Zhao Y, Gong X, Xu G, Zhang X, Chen J, Huang A. Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy. PLoS One. 2015 Jun 25;10(6):e0131337. doi: 10.1371/journal.pone.0131337. eCollection 2015. PubMed PMID: 26110616; PubMed Central PMCID: PMC4482366.

10: Yang J, Chen G, Chen X, Zhang H, Jiang D, Yang G. Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure. Virol J. 2015 Jun 24;12:97. doi: 10.1186/s12985-015-0323-3. PubMed PMID: 26104153; PubMed Central PMCID: PMC4501091.